Alaunos Therapeutics, Inc. (TCRT) stock
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.66+0.06 (+3.75%)
Close on Nov 17, 2026Market cap $4.22MP/E –Yield –
Alaunos Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Alaunos Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -135266.7%. For fiscal 2025 it was -84500.0%, against -48120.0% the year before. The highest annual figure on record is -336.4% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -84500.0% | −36380.0 |
| FY2024 | Dec 31, 2024 | -48120.0% | +637220.0 |
| FY2023 | Dec 31, 2023 | -685340.0% | −684138.6 |
| FY2022 | Dec 31, 2022 | -1201.4% | +18283.3 |
| FY2021 | Dec 31, 2021 | -19484.7% | +17437.2 |
| FY2018 | Dec 31, 2018 | -36921.9% | −36585.5 |
| FY2017 | Dec 31, 2017 | -336.4% | +2072.9 |
| FY2016 | Dec 31, 2016 | -2409.4% | +10361.8 |
| FY2012 | Dec 31, 2012 | -12771.1% | −2066.5 |
| FY2011 | Dec 31, 2011 | -10704.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -30233.3% | +143966.7 |
| Q1 FY2025 | Mar 31, 2025 | -54600.0% | +740300.0 |
| Q4 FY2024 | Dec 31, 2024 | -18875.0% | +180675.0 |
| Q2 FY2024 | Jun 30, 2024 | -29150.0% | +48313.6 |
| Q1 FY2024 | Mar 31, 2024 | -174200.0% | −173916.1 |
| Q4 FY2023 | Dec 31, 2023 | -794900.0% | −783806.8 |
| Q2 FY2023 | Jun 30, 2023 | -199550.0% | −198708.7 |
| Q4 FY2022 | Dec 31, 2022 | -77463.6% | −76645.2 |
| Q3 FY2022 | Sep 30, 2022 | -283.9% | +531.0 |
| Q1 FY2018 | Mar 31, 2018 | -11093.2% | −10218.7 |
| Q4 FY2017 | Dec 31, 2017 | -841.3% | – |
| Q3 FY2017 | Sep 30, 2017 | -818.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -814.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -874.5% | – |
See a number that looks wrong?